Shire announced a voluntary recall of 1 lot of Vyvanse (lisdexamfetamine dimesylate) 30mg capsules after a pharmacist reported a stock bottle contained an ivabradine 5mg tablet along with the Vyvanse 30mg capsules. 

The affected product has Lot #AF3360B, an expiration date of 04/2019, and is supplied in 100-count bottles. The recall was initiated to minimize the chances of adverse health consequences. Accidental ingestion of an ivabradine 5mg tablet would be unlikely to impact a patient’s medical status given its lack of drug interactions; possible cardiovascular events associated with ivabradine would not likely occur (however the drug has not been studied in pediatric or adolescent patients). 

Related Articles

Vyvanse, a central nervous system (CNS) stimulant, is a CII controlled substance indicated for use in attention deficit hyperactivity disorder and moderate-to-severe binge eating disorder. Ivabradine (marketed as CorlanorAmgen), a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with LVEF ≤35%, who are in sinus rhythm with resting heart rate ≥70bpm and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use.

Anyone in possession of the recalled lot should stop dispensing or distributing and quarantine each affected bottle.  

For more information call (800) 828-2088 or visit